How to buy Galera Therapeutics stock | $11.3

Galera Therapeutics, Inc is a biotechnology business based in the US. Galera Therapeutics shares (GRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Galera Therapeutics employs 32 staff and has a market cap (total outstanding shares value) of USD$270.7 million.

How to buy shares in Galera Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Galera Therapeutics. Find the stock by name or ticker symbol: GRTX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Galera Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$11.3, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Galera Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Galera Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Galera Therapeutics share price

Use our graph to track the performance of GRTX stocks over time.

Galera Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-27.

Latest market close	USD$11.3
52-week range	USD$5.58 - USD$19.5
50-day moving average	USD$10.8948
200-day moving average	USD$9.3291
Wall St. target price	USD$19.6
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.4013

Buy Galera Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Galera Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Galera Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Galera Therapeutics price performance over time

Historical closes compared with the close of $11.3 from 2020-12-09

1 week (2021-01-09)	N/A
1 month (2020-12-18)	1.99%
3 months (2020-10-16)	2.63%
6 months (2020-07-17)	42.68%

1 year (2020-01-17)	-15.80%
2 years (2019-01-16)	N/A
3 years (2018-01-16)	N/A
5 years (2016-01-16)	N/A

Galera Therapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-47.64%
Return on equity TTM	-271.59%
Profit margin	0%
Book value	N/A
Market capitalisation	USD$270.7 million

TTM: trailing 12 months

Shorting Galera Therapeutics shares

There are currently 120,750 Galera Therapeutics shares held short by investors – that's known as Galera Therapeutics's "short interest". This figure is 10.8% down from 135,398 last month.

There are a few different ways that this level of interest in shorting Galera Therapeutics shares can be evaluated.

Galera Therapeutics's "short interest ratio" (SIR)

Galera Therapeutics's "short interest ratio" (SIR) is the quantity of Galera Therapeutics shares currently shorted divided by the average quantity of Galera Therapeutics shares traded daily (recently around 33356.35359116). Galera Therapeutics's SIR currently stands at 3.62. In other words for every 100,000 Galera Therapeutics shares traded daily on the market, roughly 3620 shares are currently held short.

However Galera Therapeutics's short interest can also be evaluated against the total number of Galera Therapeutics shares, or, against the total number of tradable Galera Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galera Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Galera Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0162% of the tradable shares (for every 100,000 tradable Galera Therapeutics shares, roughly 16 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Galera Therapeutics.

Find out more about how you can short Galera Therapeutics stock.

Galera Therapeutics share dividends

We're not expecting Galera Therapeutics to pay a dividend over the next 12 months.

Galera Therapeutics overview

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It is also involved in developing GC4711, which is in Phase I/II clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Frequently asked questions

• What percentage of Galera Therapeutics is owned by insiders or institutions?

  Currently 10.811% of Galera Therapeutics shares are held by insiders and 81.549% by institutions.

• How many people work for Galera Therapeutics?

  Latest data suggests 32 work at Galera Therapeutics.

• When does the fiscal year end for Galera Therapeutics?

  Galera Therapeutics's fiscal year ends in December.

• Where is Galera Therapeutics based?

  Galera Therapeutics's address is: 2 West Liberty Boulevard, Malvern, PA, United States, 19355

• What is Galera Therapeutics's ISIN number?

  Galera Therapeutics's international securities identification number is: US36338D1081

• What is Galera Therapeutics's CUSIP number?

  Galera Therapeutics's Committee on Uniform Securities Identification Procedures number is: 36338D108